News &

January 04, 2019

Life Science Leader features Synspira in its Companies to Watch

SNSP113 is a glycopolymer licensed to Synspira from Synedgen as one of the first therapeutic molecules that uses this research to target airway health. SNSP113 is set to soon enter a Phase 1b clinical trial for treating cystic fibrosis (CF). SNSP113 targets biofilms and restores normal mucus in the lungs of patients with cystic fibrosis. Other compounds in the pipeline target non-CF bronchiectasis, pulmonary infection, and chronic obstructive pulmonary disease (COPD) Read on Life Science Leader